Related Experiment Video
Updated: Jan 17, 2026
In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity
Published on: November 2, 2020
CRISPR Screens Identify PIK3C2A as a Novel Mediator of EGFR Inhibitor Resistance in Head and Neck Squamous Cell
Jiayu Wang1,2, Megan L Ludwig2,3, Aditi Kulkarni2
1Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
Background:
Head and neck squamous cell carcinoma (HNSCC) is a malignancy with poor prognosis and survival. While epidermal growth factor receptor (EGFR) is a known driver of HNSCC, EGFR inhibitors show limited efficacy as monotherapies, suggesting that effective combination therapies are needed.
Methods:
We performed GeCKO and Kinase CRISPR library screens to identify candidate knockouts that increase EGFR inhibitor sensitivity in resistant HNSCC cells. We validated a candidate using the CellTiter-Glo viability assay following RNA interference and investigated the mechanisms using apoptosis and cell cycle flow cytometry analysis.
Results:
Kinase CRISPR library screens identified that PIK3C2A gene downregulation enhanced EGFR inhibitor sensitivity in resistant HNSCC cells. Viability assays further validated that PIK3C2A knockdown overcame EGFR inhibitor resistance in HNSCC cells.
Conclusions:
Our data suggests that PIK3C2A is a novel mediator of EGFR inhibitor resistance in HNSCC. Future studies are required to determine the mechanisms by which PIK3C2A drives EGFR inhibitor resistance.
Insights
Downregulating PIK3C2A enhances sensitivity to epidermal growth factor receptor (EGFR) inhibitors in head and neck squamous cell carcinoma (HNSCC). This finding offers a potential new combination therapy strategy for HNSCC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Head and neck squamous cell carcinoma (HNSCC) presents a significant clinical challenge with poor patient outcomes.
- Epidermal growth factor receptor (EGFR) signaling is implicated in HNSCC pathogenesis, yet EGFR inhibitors demonstrate limited efficacy as monotherapies.
- Novel therapeutic strategies, including combination therapies, are crucial for improving HNSCC treatment efficacy.
Purpose of the Study:
- To identify genetic targets that can re-sensitize resistant HNSCC cells to EGFR inhibitors.
- To explore potential combination therapies for overcoming EGFR inhibitor resistance in HNSCC.
Main Methods:
- Utilized GeCKO and Kinase CRISPR library screens to identify genes modulating EGFR inhibitor sensitivity in HNSCC.
- Validated candidate genes using RNA interference and cell viability assays (CellTiter-Glo).
- Investigated underlying mechanisms of resistance through apoptosis and cell cycle flow cytometry analysis.
Main Results:
- Kinase CRISPR screens revealed that downregulation of PIK3C2A significantly enhanced sensitivity to EGFR inhibitors in resistant HNSCC cells.
- PIK3C2A knockdown was confirmed to overcome EGFR inhibitor resistance in HNSCC, as demonstrated by viability assays.
- PIK3C2A emerged as a key factor in mediating resistance to EGFR-targeted therapy.
Conclusions:
- PIK3C2A acts as a novel mediator of EGFR inhibitor resistance in head and neck squamous cell carcinoma.
- Targeting PIK3C2A represents a potential therapeutic strategy to enhance the efficacy of EGFR inhibitors in HNSCC.
- Further research is warranted to elucidate the precise molecular mechanisms by which PIK3C2A contributes to EGFR inhibitor resistance.
